NCT04987281
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: Lung
Additional Notes: Patients must be undergoing a lung resection for lung metastasis
Exclusions: Patients with lesions greater than 2cm in longest diameter
https://ClinicalTrials.gov/show/NCT04987281